PBM controversies have become a major topic in the U.S. healthcare and pharmaceutical industry, particularly as regulators, lawmakers, pharmacies, and patient advocacy groups examine how Pharmacy Benefit Managers (PBMs) influence prescription drug prices and access to medicines.

Pharmacy Benefit Managers operate between pharmacies, health insurers, and drug manufacturers. They play an important role in negotiating drug prices, managing formularies, and processing prescription drug benefits. However, their business practices have increasingly attracted scrutiny, particularly from the Federal Trade Commission (FTC).

The legal conflict involving major PBMs such as CVS Caremark, Express Scripts, and Optum Rx has intensified questions about drug pricing, rebates, competition, independent pharmacies, and patient access to affordable medicines.

But what exactly is behind these PBM controversies, and why does the dispute matter to patients and pharmacy professionals?

Let's take a closer look.

What Is a Pharmacy Benefit Manager?

A Pharmacy Benefit Manager, commonly known as a PBM, is an intermediary within the U.S. prescription drug system.

PBMs work with health insurers, employers, pharmacies, and pharmaceutical manufacturers to manage prescription drug benefits.

Their responsibilities can include:

• Negotiating prices and rebates with drug manufacturers

• Developing and managing drug formularies

• Processing prescription drug claims

• Establishing pharmacy networks

• Negotiating reimbursement arrangements with pharmacies

• Managing specialty pharmacy services

• Supporting health plans with prescription drug benefit administration

PBMs therefore have considerable influence over how prescription medicines move through the healthcare system.

Why Are PBMs Facing Increased Scrutiny?

The growing attention surrounding PBM controversies is largely connected to concerns about transparency, competition, drug pricing, rebates, and pharmacy reimbursement.

Critics argue that the structure of the PBM industry can create incentives that may not always align with the interests of patients, independent pharmacies, or other participants in the pharmaceutical supply chain.

The issue has become particularly controversial because a small number of large PBMs control a substantial portion of the U.S. PBM market.

The three major PBMs frequently discussed in the debate are:

• CVS Caremark

• Express Scripts

• Optum Rx

These companies are connected to some of the largest healthcare organizations in the United States.

As a result, decisions made by PBMs can have significant consequences throughout the prescription drug market.

The FTC and PBM Controversies

The Federal Trade Commission has played a central role in the recent debate surrounding PBMs.

In July 2024, the FTC released an interim report examining the practices of the largest PBMs. The report raised concerns about the industry's influence over prescription drug pricing and access.

Among the issues examined were rebate arrangements, drug pricing, pharmacy reimbursement, and the relationship between PBMs and pharmaceutical manufacturers.

The FTC's scrutiny contributed to an increasingly heated debate about whether PBMs are helping reduce healthcare costs or whether certain business practices may contribute to higher prices.

Express Scripts vs. the FTC

One of the major developments in the PBM controversies occurred when Express Scripts challenged the FTC following the agency's scrutiny of the PBM industry.

Express Scripts argued that the FTC had presented an inaccurate and overly negative picture of PBM practices.

According to the PBM's position, PBMs can help lower healthcare costs by negotiating discounts with pharmaceutical manufacturers, managing formularies, and negotiating prices on behalf of health plans.

From this perspective, rebates and other negotiated discounts are mechanisms that can reduce costs for insurers and other healthcare stakeholders.

The disagreement therefore centers on a fundamental question:

Do PBMs ultimately reduce prescription drug costs, or can their business practices contribute to higher prices for certain medicines and patients?

The answer is complex because the U.S. prescription drug supply chain involves manufacturers, wholesalers, PBMs, insurers, pharmacies, and patients.

The FTC's Allegations Against the Major PBMs

Following the growing dispute, the FTC took further legal action involving the major PBMs.

The agency alleged that CVS Caremark, Express Scripts, and Optum Rx used their market position in ways that could contribute to higher drug costs.

One of the central areas of concern involved insulin.

The FTC alleged that certain rebate arrangements between PBMs and pharmaceutical manufacturers could create incentives around higher list prices.

The agency's concerns raised broader questions about whether patients actually benefit from negotiated rebates and how those rebates are distributed throughout the pharmaceutical supply chain.

These allegations remain part of a wider regulatory and legal debate surrounding PBM practices.

How PBM Practices May Affect Drug Prices

Understanding PBM controversies requires understanding the difference between a drug's list price and what different participants in the healthcare system ultimately pay.

PBMs negotiate with manufacturers and may receive rebates or other price concessions. They also negotiate reimbursement arrangements with pharmacies.

Critics argue that the complexity of these arrangements can make it difficult for patients and pharmacies to understand where money is flowing within the prescription drug supply chain.

For patients, this can be particularly important when their out-of-pocket costs are linked to a drug's list price or another pricing mechanism rather than the net price negotiated elsewhere in the system.

Supporters of PBMs, however, argue that their negotiating power can generate savings for health plans and employers.

This difference in perspective is one reason the debate remains so contentious.

The Impact on Independent Pharmacies

Independent pharmacies have been among the strongest critics of PBM practices.

Organizations representing community pharmacies have argued that certain PBM contracts and reimbursement arrangements can place significant financial pressure on independent pharmacies.

A pharmacy may have to purchase a medicine at a particular acquisition cost while receiving reimbursement determined by a PBM contract.

When reimbursement does not adequately cover acquisition and operating costs, pharmacies can face serious financial challenges.

For smaller pharmacies, these pressures can affect:

• Profitability

• Cash flow

• Staffing

• Medication availability

• Business sustainability

• Access to pharmacy services in local communities

Some critics therefore argue that PBM controversies are not simply about drug prices. They are also about the long-term sustainability of community pharmacy practice.

Why Insulin Became a Major Part of the Debate

Insulin has become one of the most visible examples in discussions about prescription drug pricing.

For people who depend on insulin to manage diabetes, affordability and consistent access are critical.

The FTC's scrutiny of PBMs has focused partly on the insulin market and the role of rebates and pricing arrangements.

Critics argue that complicated rebate structures may contribute to higher list prices, while PBMs have argued that their negotiations can generate savings for insurers and health plans.

This disagreement illustrates the complexity of the pharmaceutical pricing system.

PBM Reform and the Future of Drug Pricing

The legal battles involving PBMs and the FTC are part of a much broader discussion about reforming the U.S. prescription drug system.

Lawmakers and regulators have considered different approaches to increasing transparency and limiting practices they believe may contribute to higher costs.

Potential areas of reform include:

• Greater transparency around PBM contracts

• Increased disclosure of rebates and fees

• Changes to pharmacy reimbursement practices

• Restrictions on certain PBM business practices

• Greater oversight of PBM market concentration

• Measures designed to improve patient access to affordable medicines

Some states have also introduced laws targeting specific PBM practices.

What the Legal Battles Could Mean for Patients

The outcome of these legal and regulatory battles could have significant consequences for patients.

If reforms result in greater transparency and lower costs, patients could potentially benefit from more affordable prescription medicines.

However, the effects will depend on how any reforms are implemented and how different stakeholders respond.

Changes to PBM practices could also affect pharmacies, insurers, pharmaceutical manufacturers, employers, and healthcare providers.

For patients, the most important question remains relatively simple:

Will changes to the prescription drug supply chain make medicines more affordable and accessible?

That question is at the heart of the broader debate.

What Pharmacy Professionals Should Know About PBMs

Pharmacy professionals should understand the role PBMs play because their decisions can directly affect pharmacy operations and patient access to medicines.

Pharmacists and pharmacy technicians may encounter PBM-related issues involving:

• Prescription claim rejections

• Reimbursement rates

• Prior authorization requirements

• Formulary restrictions

• Preferred pharmacy networks

• Medication substitutions

• Patient out-of-pocket costs

Understanding how PBMs operate can help pharmacy professionals better understand some of the challenges patients and pharmacies encounter.

For pharmacy technicians in particular, knowledge of PBMs can strengthen their understanding of prescription processing, insurance claims, reimbursement, and patient communication.

Why PBM Controversies Matter to the Pharmacy Industry

The debate surrounding PBMs extends beyond large corporations and government agencies.

It affects the everyday experience of pharmacies and patients.

For pharmacies, PBM contracts can influence reimbursement and business sustainability.

For patients, PBM decisions can influence which medicines are covered, where prescriptions can be filled, and how much patients pay.

For pharmaceutical manufacturers, PBM negotiations can influence how medicines are positioned within formularies.

And for insurers and employers, PBMs can provide services intended to manage prescription drug spending.

This interconnected structure makes reform particularly complicated.

Conclusion

The ongoing PBM controversies involving Pharmacy Benefit Managers and the Federal Trade Commission have placed the U.S. prescription drug supply chain under renewed scrutiny.

The major issues include drug pricing, rebates, pharmacy reimbursement, competition, insulin affordability, and transparency.

PBMs argue that their negotiating power can reduce healthcare spending and provide value to insurers, employers, and patients. Critics, including independent pharmacies and some regulators, argue that certain PBM practices may contribute to higher costs and create financial pressure for pharmacies.

The legal battles between the FTC and major PBMs will continue to shape the conversation around pharmaceutical pricing and healthcare reform.

Regardless of the outcome, one thing is clear: understanding how PBMs operate is becoming increasingly important for pharmacy professionals, healthcare organizations, and patients.

As policymakers continue to examine the pharmaceutical supply chain, the future of PBMs could have a significant impact on how Americans access and pay for prescription medicines.

Pharm Tech Important Link Bank:

Here are a few helpful resources to support your pharmacy technician career:

🔗 Free CEUs for Pharmacy Technicians
https://www.pharmtechsonly.com/resource-center/free-ceus/

🔗 Search Upcoming Conventions in Your Area
https://www.pharmtechsonly.com/resource-center/conventions/

🔗 Rx Study Buddy Kit (Top 200, Math, Law)
https://www.pharmtechsonly.com/store/

🔗 Search Pharmacy Technician Jobs
https://tc.pharmtechsonly.com/careers